DURING THE ACUTE-PHASE RESPONSE (APR), plasma levels of HDL cholesterol are markedly decreased (3, 15) . Among the acute-phase proteins that might have an impact on plasma HDL cholesterol metabolism is the secretory group IIa phospholipase A 2 (sPLA 2 ). The family of phospholipase genes with a potential impact on lipoprotein metabolism is growing, with the latest discovered being phosphatidylserine-specific phospholipase A 1 (PS-PLA 1 ) (1) and lipase H (18) . sPLA 2 is a 14-kDa Ca 2ϩ -dependent enzyme that hydrolyzes phospholipids at the sn-2 position (8). sPLA 2 levels in plasma increase dramatically upon acute inflammation (27) , and plasma sPLA 2 activity has been localized to the HDL fraction in humans (9) . We recently reported that transgenic overexpression of sPLA 2 in mice in the absence of systemic inflammation has profound effects on HDL metabolism: mice overexpressing human sPLA 2 have significantly lower plasma levels of HDL cholesterol due to increased catabolism of HDL apolipoprotein A-I (apoA-I), as well as HDL cholesteryl esters (CEs) (34) . However, the physiological significance of sPLA 2 expression during acute inflammation and its effects on HDL metabolism remain unclear.
Transgenic mice overexpressing human sPLA 2 survive challenges with both Staphylococcus aureus (23) and Escherichia coli (22) better than wild-type mice, suggesting that sPLA 2 somehow protects against acute bacterial challenge. However, the mechanism(s) of this protection is unknown. We hypothesized that the metabolic effects of sPLA 2 on HDL metabolism might be related to its protective effects. For example, it is well established that human apoA-I-transgenic mice are relatively protected against endotoxin challenge (24) . In acute inflammation, the need for adrenal steroid hormone production is increased, and HDL-CEs are a source of cholesterol for steroid hormone synthesis (28, 30, 33, 41, 43) . In vitro studies (6) have suggested that sPLA 2 modification of HDL makes the CE component of the particle more accessible to selective uptake via the scavenger receptor class B type I (SR-BI) receptor. In separate experiments, we found that hepatic overexpression of SR-BI enhanced selective uptake of HDL-CE to a greater extent in sPLA 2 /apoA-I-double transgenic mice than in apoA-I-transgenic mice (Tietge UJF, unpublished data). Thus one possible function of sPLA 2 might be to enhance the uptake of HDL-CEs into the adrenals to meet the requirements for increased steroid hormone synthesis.
Therefore, the purpose of our study was to test the hypothesis that sPLA 2 induction during the APR in-creases the selective uptake of HDL-CE into the adrenals in vivo. The human sPLA 2 -transgenic mouse model we utilized in our previous study (34) represents an ideal tool for addressing this question, because the sPLA 2 transgene expression is controlled by its own promoter and thereby confers upregulated sPLA 2 expression in response to inflammatory stimuli (23) . Therefore, we used human sPLA 2 -transgenic and C57BL/6 mice, which lack endogenous sPLA 2 (19) , to perform a series of HDL kinetic studies after induction of the APR with bacterial lipopolysaccharide (LPS) to assess plasma catabolism and tissue uptake of HDL apoproteins as well as HDL-CEs. Our data indicate that, in human sPLA 2 -transgenic mice, upregulation of sPLA 2 in response to acute inflammation results in significantly increased selective uptake of HDL-CE into the adrenals, suggesting a potentially important novel physiological function of sPLA 2 .
EXPERIMENTAL PROCEDURES
Animal studies. The human group II sPLA2-transgenic mice used in this study have been described previously (13, 34) . Briefly, a 6.2-kb HindIII restriction fragment, containing all five exons and 1.6 kb of nucleotides upstream from the RNA initiation site and 0.35 kb of nucleotides downstream of the polyadenylation signal sequence of the human sPLA 2 gene, was used to generate transgenic mice by standard procedures. The sPLA 2-transgenic line has been backcrossed to the C57BL/6 background. Nontransgenic littermates from further breeding of sPLA 2-transgenic mice with wild-type C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were used as controls. The animals were caged in animal rooms with alternating 12-h periods of light (7 AM-7 PM) and dark (7 PM-7 AM) and with ad libitum access to water and mouse chow diet.
The APR was induced by intraperitoneal injection of 40 g of LPS (E. coli 0111:B4, Difco Laboratories, Detroit, MI) (16) or sterile saline. Blood was obtained by retroorbital bleeding before injection and 10 h after injection for determination of plasma lipid and lipoprotein levels. At the 10-h time point, mice were injected with the radiotracers, and the HDL kinetic studies were carried out as described below.
Plasma lipid and lipoprotein analysis. Mice were bled from the retroorbital plexus by use of heparinized capillary tubes. Blood was drawn into tubes containing 2 mM EDTA, 0.2% NaN 3, and 1 mM benzamidine. Aliquots were stored at Ϫ20°C until analysis. Plasma total cholesterol, HDL cholesterol, triglycerides, phospholipids, and human apoA-I levels were determined on a Cobas Fara (Roche Diagnostics Systems, Nutley, NJ) by use of Sigma Diagnostics reagents (Sigma Diagnostics, St. Louis, MO).
Western blotting. Western blot analysis for human group II sPLA 2 was performed, as previously described (34) , with a monoclonal mouse anti-human sPLA2 primary antibody at a concentration of 2 g/ml (Boehringer Mannheim, Mannheim, Germany) and the enhanced chemiluminescence (ECL) detection system (Amersham, Arlington Heights, IL).
HDL metabolic studies. Autologous HDL was prepared from pooled mouse plasma by sequential ultracentrifugation (density: 1.063 Ͻ d Ͻ 1.21). After extensive dialysis against Fig. 1 . Western blot analysis for human secretory phospholipase A2 (sPLA2) in plasma from sPLA2-transgenic mice at baseline (0 h) and 10 h after injection with either saline or LPS as indicated. Samples were resolved by SDS-PAGE under nondenaturing conditions. Human sPLA2 was visualized using a monoclonal mouse anti-human sPLA2 antibody, as described in EXPERIMENTAL PROCEDURES. sterile PBS containing 0.01% EDTA, one part of the HDL was labeled with 125 I-tyramine-cellobiose (TC), as previously described (34) . Unbound iodine was removed by passing the solution over a Sephadex G25 desalting column (Amersham Pharmacia Biotech). Finally, the HDL was reisolated by ultracentrifugation (density: 1.063 Ͻ d Ͻ1.21), extensively dialyzed, sterile filtered, and stored at 4°C until use (34) . The other part of the isolated mouse HDL was labeled with cholesteryl hexadecyl ether (cholesteryl-1,2-3 H, NEN Life Sciences Products) according to a previously published methodology (34) . After labeling, the HDL was reisolated by ultracentrifugation (density: 1.063 Ͻ d Ͻ1.21), extensively dialyzed, sterile filtered, and stored at 4°C until injection.
To assess the rates of plasma catabolism and to measure the organ uptake of the different tracers, 1 Ci of the 125 I-TC-HDL and 1 million dpm of the [ 3 H]CE-HDL were coinjected via the tail veins into mice from the different experimental groups. Blood samples were drawn by retroorbital bleeding at 5 min, 1 h, 3 h, 6 h, 11 h, and 24 h (ϳ25 l at each time point). An aliquot of 10 l of plasma from each time point was counted using a Cobra II ␥-counter (Packard Instruments, Downers Grove, IL). These data were used to generate the plasma disappearance curves for HDL apolipoproteins. After ␥-counting, the same samples were extracted with the method described by Dole (7) . The lipid phases were harvested, and aliquots were counted on a scintillation counter (Beckman LS6500; Beckman Instruments, Palo Alto, CA). From these data, plasma disappearance curves for HDL-CEs were calculated. The recovery of [ 3 H]cholesteryl ether after lipid extraction was 97.5 Ϯ 1.9%. Contamination of the extracted 3 H-labeled lipids with 125 I was Ͻ0.5%. Plasma decay curves for both tracers were generated by dividing the plasma radioactivity at each time point by the radioactivity at the initial 5-min time point after tracer injection. Fractional catabolic rates (FCRs) were determined from the area under the plasma disappearance curves fitted to a bicompartmental model by use of the SAAM II program (2) .
To measure the organ uptake of HDL apolipoproteins and HDL-CEs, mice were anesthetized with an intraperitoneally injected ketamine-xylazine mixture and perfused extensively with cold PBS by cardiac puncture (34) . Then liver, spleen, kidney, and adrenals were harvested. First, radioactivity uptake ( 125 I) into the different organs was assessed by ␥-counting to determine uptake of HDL apolipoproteins. Then, the different organs were extracted using the Dole method, and the amount of [ 3 H]cholesteryl ether taken up into each organ was determined on a scintillation counter (Beckman LS6500). Organ uptake for each tracer was expressed as a percentage of the injected dose. The injected dose was calculated by multiplying the initial plasma counts (5-min time point) with the estimated plasma volume (3.5% of total body wt). Selective uptake into each organ was determined by subtracting the percentage of the injected dose of 125 I-HDL recovered in each organ from the percentage of the injected dose of [ 3 H]HDL-CE and correcting the value for tissue weight. Values were expressed as micrograms of tissue weight for each organ.
Statistical analysis. Values are presented as means Ϯ SE unless otherwise indicated. Results were analyzed by ANOVA and Student's t-test using the GraphPad Prism Software (GraphPad, San Diego, CA). Statistical significance for all comparisons was assigned at P Ͻ 0.05. 
RESULTS
In sPLA 2 -transgenic mice, injection of saline did not result in any detectable change in plasma sPLA 2 , whereas plasma sPLA 2 was increased 10 h after induction of the APR by injection of LPS (Fig. 1 ). These data, consistent with a previous report (23) , demonstrate that the sPLA 2 in these transgenic mice is upregulated by acute inflammation. At baseline, sPLA 2 -transgenic mice had significantly lower plasma levels of total cholesterol (61 Ϯ 3 vs. 85 Ϯ 7 mg/dl, P Ͻ 0.01, Fig. 2A and Table 1 ), HDL-cholesterol (HDL-C; 44 Ϯ 3 vs. 64 Ϯ 5 mg/dl, P Ͻ 0.01, Fig. 2B , Table 1 ), and phospholipids (116 Ϯ 9 vs. 179 Ϯ 4 mg/dl, P Ͻ 0.01, Fig. 2C and Table  1 ) compared with wild-type mice, consistent with our previous report (34) . In both saline-injected groups, plasma lipid levels remained relatively unchanged compared with baseline values (Fig. 2, A-C) . After LPS challenge in wild-type mice, plasma total and HDL-C levels did not change significantly compared with baseline values (Fig. 2, A and B) , but plasma phospholipid levels decreased significantly by 19 Ϯ 10% (P Ͻ 0.05 compared with baseline values, Fig. 2C ). In contrast, in sPLA 2 -transgenic mice, plasma levels of total cholesterol and HDL-C decreased significantly after LPS injection compared with baseline values (Ϫ12 Ϯ 5%, P Ͻ 0.05, Fig. 1A ; Ϫ18 Ϯ 6%, P Ͻ 0.01, Fig. 1B , respectively), and phospholipids also decreased by 11 Ϯ 6% (Fig. 1C , P Ͻ 0.05 compared with baseline values). Thus absence of sPLA 2 is associated with a lack of HDL response to endotoxin, whereas expression of inducible sPLA 2 confers responsiveness to LPS injection with regard to reduction of HDL-C levels.
To assess the metabolic basis for the changes in HDL, we performed a series of HDL metabolism studies simultaneously tracing the catabolism of both HDL apolipoproteins and HDL-CEs in wild-type and sPLA 2 -transgenic mice in reponse to endotoxin injection. We determined the rate and sites of HDL apolipoprotein catabolism by using 125 I-TC-HDL as a tracer. Salineinjected sPLA 2 -transgenic mice had significantly faster Fig. 4 . Tissue sites of catabolism of 125 I-TC-labeled autologous HDL in sPLA2-transgenic (tg) and control mice after the injection of either saline or LPS. Labeled HDL was prepared as described in EXPERIMENTAL PROCEDURES and injected via the tail vein into sPLA2-transgenic and control mice 10 h after induction of the APR or injection of saline. After 24 h, mice were killed and thoroughly perfused with PBS, and the respective tissues were harvested. Uptake of radioactivity into the respective organs was determined by ␥-counting. Data represent percentages of injected tracer dose recovered in liver (A), spleen (B), kidneys (C), and adrenals (D). Statistically significant differences (P Ͻ 0.05) are as assessed by independent sample t-test: *between saline-injected controls and LPS-injected mice, and #between sPLA2-transgenic and wild-type mice. plasma catabolism of HDL apolipoproteins compared with saline-injected wild-type controls, (0.18 Ϯ 0.01 vs. 0.10 Ϯ 0.01 pool/h, P Ͻ 0.001, Fig. 3 , A and B, and Table 2 ), consistent with our previous observations (34) . LPS injection had no significant effect on the catabolic rate of HDL apolipoproteins in wild-type control mice (Table 2) . On the other hand, in sPLA 2 -transgenic mice, the FCR of HDL apolipoproteins increased significantly in response to LPS (0.21 Ϯ 0.01 pool/h, P Ͻ 0.05, Fig. 3B and Table 2 ). These data demonstrate that upregulation of the sPLA 2 transgene is required to mediate the effect of LPS injection on HDL apolipoprotein catabolism.
Use of the trapped ligand 125 I-TC-HDL allowed us to determine the tissue sites of HDL apolipoprotein uptake. Uptake of HDL apolipoproteins into the liver was not significantly different between saline-injected sPLA 2 -transgenic mice and wild-type controls. However, after LPS administration, hepatic uptake of the 125 I-TC-HDL tracer increased in wild-type mice (18 Ϯ 2 to 27 Ϯ 2% of injected dose, P Ͻ 0.001, Fig. 4A ) and in sPLA 2 -transgenic mice (15 Ϯ 3 to 33 Ϯ 3% of injected dose, P Ͻ 0.001, Fig. 4A ). There was no difference in HDL apolipoprotein uptake into the spleen between the saline-injected groups of experimental mice. After induction of the APR, there was a significant increase in HDL apolipoprotein uptake into the spleen in wildtype (0.7 Ϯ 0.2 to 2.3 Ϯ 0.3% of injected dose, P Ͻ 0.001, Fig. 4B ) and sPLA 2 -transgenic mice (1.0 Ϯ 0.2 to 2.1 Ϯ 0.3% of injected dose, P Ͻ 0.01, Fig. 4B ). HDL apolipoprotein catabolism by the kidneys was significantly higher in saline-injected sPLA 2 -transgenic mice than in the wild-type mice (8 Ϯ 1 to 5 Ϯ 1% of injected dose, P Ͻ 0.001), as we previously reported (34), but did not change significantly in either group after injection with LPS (Fig. 4C) . Uptake of HDL apolipoproteins into the adrenals was extremely low relative to liver and kidney (Fig. 4D) .
We also investigated the plasma catabolism of HDL-CE by using as a tracer HDL labeled with [ 3 H]cholesteryl ether in the same mice used for the HDL apolipoprotein kinetic studies described above. Human sPLA 2 -transgenic mice injected with saline had significantly faster plasma catabolism of HDL-CE than saline-injected control mice (0.31 Ϯ 0.02 vs. 0.22 Ϯ 0.02 pool/h, P Ͻ 0.001, respectively; Fig. 5, A and B, and Table 2 ), consistent with our previous report (34) . LPS injection had no significant effect on plasma catabolism of HDL-CE in wild-type mice (Fig.  5A, Table 2 ). However, in sPLA 2 -transgenic mice, LPS injection resulted in a significant increase in the FCR of HDL-CE (0.42 Ϯ 0.05 pool/h, P Ͻ 0.05, Fig. 5B , Table  2 ). This indicates that upregulation of the sPLA 2 transgene is required to mediate the effects of LPS injection on HDL-CE catabolism.
The use of the nonhydrolyzable CE analog [ 3 H]cholesteryl ether enabled the determination of sites of tissue catabolism of HDL-CEs. LPS injection significantly increased hepatic HDL-CE uptake in wild-type mice (44 Ϯ 3 to 52 Ϯ 4% of injected dose, P Ͻ 0.05, Fig.  6A ); in sPLA 2 -transgenic mice, tracer uptake into the liver was nonsignificantly increased (70 Ϯ 4 to 78 Ϯ 4% of injected dose, P ϭ 0.06, Fig. 6A ). Uptake of HDL-CE into the spleen was increased in both groups of LPSinjected mice, although only in wild-type mice did this increase reach the level of statistical significance (P Ͻ 0.05, Fig. 6B ). There were no significant changes in the small amount of HDL-CE uptake into the kidneys between the different experimental groups of mice (Fig. 6C) . Saline-injected sPLA 2 -transgenic mice had significantly higher uptake of HDL-CE into their adrenals compared with wild-type controls (0.82 Ϯ 0.06 vs. 0.51 Ϯ 0.06% of injected dose, P Ͻ 0.001, Fig. 6D ), consistent with our previous report (34) . HDL-CE uptake into the adrenals increased significantly in both LPS-injected sPLA 2 -transgenic mice (1.43 Ϯ 0.11% of injected dose, P Ͻ 0.001, Fig. 6D ) and LPS-injected After tracer administration, blood samples were drawn at time points indicated, samples were extracted according to the Dole method, and radioactivity in the lipid phase was determined by scintillation counting. Values are fractions of injected dose remaining at each time point. Curves were analyzed using a bicompartmental model on the SAAMII program, and FCR values were calculated. A: wild-type C57BL/6 control mice; B: sPLA2-transgenic mice. FCR values of saline-injected sPLA2-transgenic mice were significantly higher than those of controls (P Ͻ 0.001). FCR values of LPS-injected sPLA2-transgenic mice were significantly increased compared with saline-injected sPLA2 mice (P Ͻ 0.05).
wild-type mice (0.82 Ϯ 0.06% of injected dose, P Ͻ 0.001, Fig. 6D ).
Because the HDL apolipoprotein and HDL-CE kinetic experiments were carried out in the same mice, we used both measurements to determine the selective uptake of CE from HDL into respective organs in response to LPS injection. sPLA 2 -transgenic mice injected with saline had significantly higher HDL-CE selective uptake into the liver (34 Ϯ 2 vs. 25 Ϯ 3%/g tissue protein, P Ͻ 0.05, Fig. 7A ) compared with salineinjected wild-type controls, but LPS injection had no significant effect on hepatic selective uptake of HDL-CE in either group (Fig. 7A) . Likewise, there was little effect of LPS on selective uptake of HDL-CE in the spleen in either group. In the kidneys, there was significantly higher "negative selective uptake" (i.e., lipid-poor protein uptake) in saline-injected sPLA 2 -transgenic mice compared with wild-type mice (Ϫ23 Ϯ 2 vs. Ϫ17 Ϯ 2%/g, P Ͻ 0.01, Fig. 7C ), and this was relatively unaffected by LPS injection (Fig. 7C) . In the adrenals, HDL-CE selective uptake after LPS injection was 2.4-fold higher in sPLA 2 -transgenic mice compared with wild-type mice (156 Ϯ 6 vs. 65 Ϯ 5%/g tissue protein, P Ͻ 0.001, Fig. 7D ).
DISCUSSION
The results of this study demonstrate that upregulation of sPLA 2 expression by endotoxin injection significantly enhances the plasma catabolism of HDL, results in altered tissue uptake of HDL apolipoproteins and HDL-CE, and specifically increases the selective uptake of HDL-CE into the adrenals, suggesting a novel and important metabolic in vivo role of sPLA 2 .
The line of sPLA 2 -transgenic mice used in the present study was made with a genomic construct that results in relatively high baseline sPLA 2 expression but also preserves the inducibility of the transgene in response to inflammatory stimuli (23) . This allowed us to study the effects of acute inflammation on HDL metabolism in human sPLA 2 -transgenic mice on a C57BL/6 genetic background compared with wild-type C57BL/6 mice lacking the endogenous mouse sPLA 2 enzyme due to a frameshift mutation in the respective gene (19) . At baseline, sPLA 2 -transgenic mice have lower plasma levels of HDL-C compared with wild-type mice (34) . The underlying metabolic mechanism is a significantly increased rate of plasma catabolism of HDL apolipoproteins as well as HDL-CE (34), a finding that we confirmed in the current studies. In these studies, induction of the APR in wild-type C57BL/6 mice neither altered the steady-state plasma concentrations of HDL-C nor affected the catabolic rates of HDL apolipoproteins or HDL-CE. In contrast, in sPLA 2 -transgenic mice, induction of the APR resulted in increased sPLA 2 expression and a significant decrease in HDL-C levels. The FCRs of both HDL apoli- Fig. 6 . Tissue sites of catabolism of [ 3 H]cholesteryl ether-labeled autologous HDL in sPLA2-transgenic and control mice after injection of either saline or LPS. Labeled HDL was prepared as described in EXPERIMENTAL PROCEDURES and injected via the tail vein into sPLA2-transgenic and control mice 10 h after induction of APR or injection of saline. After 24 h, mice were killed and thoroughly perfused with PBS, and the respective tissues were harvested. Organs were extracted according to the Dole method, and radioactivity in the lipid phase was determined by scintillation counting. Data represent percentages of injected tracer dose recovered in liver (A), spleen (B), kidneys (C), and adrenals (D). Statistically significant differences (P Ͻ 0.05) are as assessed by independent sample t-test: *between saline-injected controls and LPS-injected mice; #between sPLA2-transgenic and wildtype mice.
poproteins and HDL-CE increased significantly in sPLA 2 -transgenic mice in response to LPS injection. These results indicate that the presence of an inducible and functional sPLA 2 gene is required to mediate the effects of acute inflammation on HDL metabolism in mice. In parallel and separate experiments, we crossed human sPLA 2 -transgenic mice with human apoA-Itransgenic mice and found, consistent with the present results, that upregulation of sPLA 2 expression was required for an effect of LPS on plasma HDL-C and apoA-I levels (35) .
There are three possible pathways for the cellular uptake of HDL-C: 1) holoparticle uptake of HDL, 2) selective uptake of HDL-C mediated by the SR-BI receptor, and 3) transfer to LDL by CE transfer protein (CETP) and uptake via the LDL receptor. The latter pathway is not active in mice, because this species is lacking CETP. Holoparticle uptake of HDL is a known mechanism for removal of HDL from the circulation (11, 12, 32, 42) . One possible receptor for this process is cubilin (26) , which may have a role in the renal and placental uptake of HDL (14, 20) . In the liver, other poorly characterized mechanisms appear to exist that mediate holoparticle catabolism of HDL. Our data demonstrate that, during the APR, a substantial increase in the hepatic uptake of HDL apolipoprotein and CE occurs, with holoparticle uptake being the most likely mechanism. This process appears to be relatively unaffected by sPLA 2 . Likewise, there was no significant change in HDL apolipoprotein uptake by the kidneys in sPLA 2 -transgenic mice after induction of the APR. Therefore, our data suggest that sPLA 2 has relatively little, if any, effect on holoparticle HDL uptake by the liver or kidney.
SR-BI has been extensively studied as a receptor that mediates the selective uptake of HDL-C (21, 36, 40) . Liver and steroidogenic organs are tissues with high SR-BI expression (21, 31) . Previous in vivo studies have established that liver, and especially the adrenals, have high rates of selective uptake of HDL CE (4, (10) (11) (12) . By simultaneously using trapped ligands for HDL apolipoproteins ( 125 I-TC) as well as HDL-CE ([ 3 H]cholesteryl ether) in the same mice, we quantitated selective HDL-CE uptake in specific tissues in sPLA 2 -transgenic mice in response to the APR. Transgenic expression of sPLA 2 significantly increased the selective uptake of HDL-CE in both liver and adrenals at baseline. Induction of the APR did not significantly increase selective HDL-CE uptake in the liver in either wild-type or sPLA 2 -transgenic mice. In contrast, induction of the APR induced a significant increase in selective HDL-CE uptake in the adrenals in wild-type mice and especially in sPLA 2 -transgenic mice. The rate of selective HDL-CE uptake in LPS-injected sPLA 2 -transgenic mice was 2.4-fold that in LPS-injected wildtype mice, indicating that sPLA 2 expression and up- 125 I-TC-labeled HDL uptake (% of injected dose) was subtracted from [ 3 H]cholesteryl ether-labeled HDL uptake (% of injected dose) into the respective organs [liver (A), spleen (B), kidneys (C), and adrenals (D)] to calculate selective uptake, and data were referred to as g of tissue wt. Statistically significant differences (P Ͻ 0.05) are as assessed by independent sample t-test: *between saline-injected controls and LPS-injected mice; #between sPLA2-transgenic and wildtype mice.
regulation by inflammation markedly increase cholesterol uptake from HDL by the adrenals. The most striking metabolic difference between sPLA 2 -transgenic mice and wild-type littermates after the induction of the APR is the magnitude of selective uptake into the adrenals. Although not specifically explored in this study, there is also the possibility of sPLA 2 -mediated targeting of HDL CE to monocytes/macrophages during the APR, because SR-BI is expressed on these cells (36) .
Expression of sPLA 2 confers protection of mice against bacterial infections, which has been demonstrated for gram-positive (23) as well as gram-negative (22) bacterial strains. This has been ascribed at least in part to a direct bactericidal effect of the enzyme (37, 38) , possibly due to degradation of bacterial surface phospholipids (39) . However, although sPLA 2 is able to kill gram-positive bacteria in vitro (29, 38) , an efficient defense against gram-negative bacteria requires additional cofactors, such as components of the complement system (25, 39) . Furthermore, neither serum nor peritoneal lavage fluid from sPLA 2 -transgenic mice was bactericidal against E. coli in vitro (22) , suggesting that other properties of sPLA 2 may have resulted in the increased survival of sPLA 2 -transgenic mice challenged with bacteria. During acute inflammation, there is a requirement of increased adrenal steroid hormone synthesis, for which HDL-CE is a known source (17, 28, 30, 41) .
Our results suggest that one possible physiological role of the sPLA 2 enzyme during inflammation is to modify HDL to make HDL CE more accessible for selective uptake into the adrenals. There are three main families of steroid hormones synthesized by the adrenal cortex: mineralocorticoids in the zona glomerulosa, glucocorticoids in the zona fasciculata, and androgens in the zona reticularis (5, 41) . Both mineralocorticoids and glucocorticoids could be helpful in the response to acute inflammation. Although there might be species differences in the preferential usage of LDL-or HDL-CE for steroid hormone synthesis (36), a significantly higher expression of SR-BI in the zona fasciculata of the adrenal cortex in mice compared with the zona glomerulosa has been reported (30) . SR-BI-mediated uptake is most likely the major route for the delivery of HDL-CE to the steroidogenic pathway in the adrenals (36, 41) . It is therefore probable that, during the APR, CE from sPLA 2 -modified HDL is preferentially taken up by zona fasciculata cells and used for glucocorticoid synthesis. This extends the role of sPLA 2 in the host response to bacterial infections beyond a direct antibacterial effect and might contribute to the significantly increased survival of sPLA 2 -transgenic mice in response to a bacterial challenge.
In summary, we characterized changes in HDL catabolism during the APR in wild-type and sPLA 2 -transgenic mice. Both groups of mice had increased holoparticle catabolism by the liver and increased selective HDL-CE uptake by the adrenals in response to LPS injection. The sPLA 2 -transgenic mice demonstrated an especially robust increase in adrenal selective HDL-CE uptake in response to induction of the APR. We suggest that one physiological in vivo role of sPLA 2 is to significantly increase selective HDL-CE uptake by the adrenals to help meet the requirements of increased steroid hormone synthesis during acute systemic inflammation. This metabolic effect might be beneficial in the response to bacteremia and other acute inflammatory insults and might contribute to improved host survival in this setting.
